PITTSBURGH — A consumer has filed a class action lawsuit against Solco Healthcare U.S. LLC, Zhejiang Huahai Pharmaceuticals, and Prinston Pharmaceutical Inc., citing alleged liability and negligence.
Valerie Rodich-Annese filed a complaint individually and on behalf of all others similarly situated on Jan. 16 in the U.S. District Court for the Western District of Pennsylvania against the defendants, alleging they failed to conduct proper testing of medication.
According to the complaint, the plaintiff alleges she and other similarly situated individuals were subjected to significant risk of bodily injury or death for having consumed medications containing Valsartan as an active ingredient.
Valsartan, an angiotensin II receptor blocker (ARB) used to treat high blood pressure and heart failure, was discovered to be defective and unsafe for its intended use because it contain high-levels of N-nitrosodimethylamine (NDMA), which is classified as a probable human carcinogen that increases the risk of cancer, the suit says.
The plaintiff holds Solco Healthcare U.S. LLC, Zhejiang Huahai Pharmaceuticals, and Prinston Pharmaceutical Inc. responsible because the defendants allegedly failed to conduct adequate safety and efficacy testing, and failed to conduct and document a formal risk assessment.
The plaintiff requests a trial by jury and seeks judgment against the defendants, certification of the class-action status, declaratory relief, costs and disbursements, attorneys' fees, interest, and other relief as may be appropriate. She is represented by D. Aaron Rihn of Robert Peirce & Associates PC in Pittsburgh and Nicholas Migliaccio and Jason Rathod of Migliaccio & Rathod LLP in Washington.
The U.S. District Court for the Western District of Pennsylvania Case No. is 19-cv-00046.